Definium Therapeutics (DFTX) said late Monday it intends to offer $500 million shares and pre-funded warrants in an underwritten public offering, with underwriters granted a 30-day option to purchase up to $75 million additional shares.

Proceeds will be used among others for research and development, and general corporate purposes, the company said.